Clinical data | |
---|---|
Routes of administration |
? |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | 14198-28-8 |
PubChem (CID) | 3036246 |
ChemSpider | 2300306 |
ChEMBL | CHEMBL330376 |
ECHA InfoCard | 100.162.264 |
Chemical and physical data | |
Formula | C17H23NO |
Molar mass | 257.37 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM). It has no significant affinity for the σ2 receptor. Alazocine also acts as a κ-opioid receptor partial agonist (Ki = 0.4 nM; EC50 = 24 nM; Emax = 66%), and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).